ADC Therapeutics Announces Plan To Discontinue Phase 2 LOTIS-9 Clinical Trial Of ZYNLONTA And Rituximab In Unfit Or Frail Previously Untreated DLBCL Patients
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics has announced its plan to discontinue the Phase 2 LOTIS-9 clinical trial of ZYNLONTA and Rituximab in unfit or frail previously untreated DLBCL patients.
July 20, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ADC Therapeutics' decision to discontinue the Phase 2 LOTIS-9 clinical trial could potentially impact the company's stock negatively in the short term.
The discontinuation of a clinical trial often indicates issues with the drug's efficacy or safety, which could negatively impact investor sentiment and the company's stock price. However, the exact impact will depend on the importance of this trial to ADC Therapeutics' overall pipeline and strategy.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100